Ipsen: agreement to acquire Epizyme

(CercleFinance.com) - Ipsen today announced that it has entered into a definitive agreement to acquire Epizyme, a biopharmaceutical company that is committed to developing and delivering innovative treatments through novel epigenetic drugs for cancer patients.


The acquisition focuses on Epizyme's lead drug, Tazverik (tazemetostat), a first-in-class, chemotherapy-free EZH2 inhibitor approved by the US regulatory authorities on a fast-track basis in 2020.

Ipsen will launch a tender offer for the outstanding shares of Epizyme at a price of 1.45 dollar per share in cash at closing, for an initial estimated total consideration of 247 million dollars, plus one guaranteed value certificate (GVC) per share.

The transaction, which was unanimously approved by Ipsen and Epizyme's respective boards of directors, is expected to close by the end of Q3 2022, subject to the satisfaction of all closing conditions.


Copyright (c) 2022 CercleFinance.com. All rights reserved.